Evolving Risk Classifications in AML in a Real-Life Scenario: After Changes upon Changes, Is It More and More Adverse?

Patients from the ELN2022 adverse-risk AML group had more mutations per patient (median 3 (range 1–6)) compared to other groups, though the differences between the groups did not reach statistical significance ( p = 0.145).

also in 111,027 other papers